TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF EUROPE COLORECTAL SURGICAL DEVICES MARKET 24
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET APPLICATION COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PESTEL ANALYSIS 43
4.2 PORTERS FIVE FORCES 44
5 INDUSTRIAL INSIGHTS: 45
CONCLUSION: 45
6 EUROPE COLORECTAL SURGICAL DEVICES MARKET: REGULATIONS 46
6.1 REGULATION IN U.S 46
6.2 REGULATION IN EUROPE 47
6.3 REGULATION IN CANADA 47
6.4 REGULATION IN SOUTH AFRICA 48

7 MARKET OVERVIEW 49
7.1 DRIVERS 51
7.1.1 INCREASE IN GERIATRIC POPULATION 51
7.1.2 RISE IN NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS 51
7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 52
7.1.4 RISE IN PREVALENCE OF COLORECTAL CANCER 53
7.2 RESTRAINTS 54
7.2.1 HIGH COST OF COLORECTAL SURGERY DEVICES 54
7.2.2 STRICT REGULATIONS 54
7.3 OPPORTUNITIES 55
7.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS AND GOVERNMENT 55
7.3.2 INCREASE IN MINIMAL INVASIVE SURGERY PROCEDURE 55
7.3.3 RISING DISPOSABLE INCOME 56
7.4 CHALLENGES 56
7.4.1 COMPLICATIONS ASSOCIATED WITH PROCEDURE 56
1.4.1 SHORTAGE OF SKILLED PERSONNEL 57
8 EUROPE COLORECTAL SURGICAL DEVICES MARKET, BY PRODUCT TYPE 58
8.1 OVERVIEW 59
8.2 ENDOSCOPE 62
8.2.1 LAPAROSCOPE 63
8.2.2 COLONSCOPE 63
8.3 ELECTROSURGERY 63
8.3.1 INSTRUMENTS 64
8.3.2 ACCESSORIES 64
8.4 HANDHELD INSTRUMENTS 64
8.4.1 SCISSORS 65
8.4.2 FORCEPS 65
8.4.3 OTHERS 65
8.5 SEALING DEVICES 66
8.6 SURGICAL STAPLING DEVICES 67
8.7 ACCESSORIES 68
9 EUROPE COLORECTAL SURGICAL DEVICES MARKET, BY INDICATION 69
9.1 OVERVIEW 70
9.2 COLORECTAL CANCER 73
9.3 DIVERTICULITIS 74
9.4 ULCERATIVE COLITIS 75
9.5 CROHN'S DISEASE 76
9.6 OTHERS 77
10 EUROPE COLORECTAL SURGICAL DEVICES MARKET, BY END USER 78
10.1 OVERVIEW 79
10.2 SURGICAL CENTERS 82
10.3 HOSPITALS 83
10.4 CLINICS 84
10.5 OTHERS 85
11 EUROPE COLORECTAL SURGICAL DEVICES MARKET, BY REGION 86
11.1 EUROPE 87
11.1.1 GERMANY 93
11.1.2 FRANCE 95
11.1.3 U.K. 97
11.1.4 ITALY 99
11.1.5 SPAIN 101
11.1.6 TURKEY 103
11.1.7 RUSSIA 105
11.1.8 NETHERLANDS 107
11.1.9 SWITZERLAND 109
11.1.10 BELGIUM 111
11.1.11 REST OF EUROPE 113
12 EUROPE COLORECTAL SURGICAL DEVICES MARKET: COMPANY LANDSCAPE 114
12.1 COMPANY SHARE ANALYSIS: EUROPE 114
13 COMPANY PROFILE 115
13.1 MEDTRONIC 115
13.1.1 COMPANY SNAPSHOT 115
13.1.2 REVENUE ANALYSIS 116
13.1.3 COMPANY SHARE ANALYSIS 116
13.1.4 PRODUCT PORTFOLIO 116
13.1.5 RECENT DEVELOPMENT 117
13.1.5.1 Product Launch 117
13.2 STRYKER 118
13.2.1 COMPANY SNAPSHOT 118
13.2.2 REVENUE ANALYSIS 118
13.2.3 COMPANY SHARE ANALYSIS 119
13.2.4 PRODUCT PORTFOLIO 119
13.2.5 RECENT DEVELOPMENTS 120
13.2.5.1 ACQUISITION 120

13.3 JOHNSON & JOHNSON SERVICES, INC 121
13.3.1 COMPANY SNAPSHOT 121
13.3.2 REVENUE ANALYSIS 121
13.3.3 COMPANY SHARE ANALYSIS 122
13.3.4 PRODUCT PORTFOLIO 122
13.3.5 RECENT DEVELOPMENTS 122
13.3.5.1 FDA Clearance 122
13.3.5.2 Study Results 122
13.4 BOSTON SCIENTIFIC CORPORATION 124
13.4.1 COMPANY SNAPSHOT 124
13.4.2 REVENUE ANALYSIS 124
13.4.3 COMPANY SHARE ANALYSIS 125
13.4.4 PRODUCT PORTFOLIO 125
13.4.5 RECENT DEVELOPMENTS 125
13.4.5.1 Product Launch 125
13.4.5.2 Agreement 126
13.5 KARL STORZ SE & CO. KG 127
13.5.1 COMPANY SNAPSHOT 127
13.5.2 COMPANY SHARE ANALYSIS 127
13.5.3 PRODUCT PORTFOLIO 128
13.5.4 RECENT DEVELOPMENTS 128
13.5.4.1 CONTRACT 128
13.5.4.2 INVESTMENT 129
13.6 BD 130
13.6.1 COMPANY SNAPSHOT 130
13.6.2 REVENUE ANALYSIS 130
13.6.3 PRODUCT PORTFOLIO 131
13.6.4 RECENT DEVELOPMENT 131
13.6.4.1 ACQUISITION 131
13.7 BIPAD SURGICAL, INC 132
13.7.1 COMPANY SNAPSHOT 132
13.7.2 PRODUCT PORTFOLIO 132
13.7.3 RECENT DEVELOPMENT 132
13.7.3.1 FDA APPROVAL 132
13.8 CARDINAL HEALTH 133
13.8.1 COMPANY SNAPSHOT 133
13.8.2 REVENUE ANALYSIS 133
13.8.3 PRODUCT PORTFOLIO 134
13.8.4 RECENT DEVELOPMENTS 134
13.8.4.1 NEW DISTRIBUTION CENTER 134
13.8.4.2 NEW DISTRIBUTION CENTER 134
13.9 COOK GROUP 135
13.9.1 COMPANY SNAPSHOT 135
13.9.2 PRODUCT PORTFOLIO 135
13.9.3 RECENT DEVELOPMENTS 136
13.9.3.1 ISO CERTIFICATION 136
13.9.3.2 INVESTMENT 136
13.10 CONMED CORPORATION 137
13.10.1 COMPANY SNAPSHOT 137
13.10.2 REVENUE ANALYSIS 137
13.10.3 PRODUCT PORTFOLIO 138
13.10.4 RECENT DEVELOPMENT 138
13.10.4.1 CONFERENCE 138
13.11 HALLMARK SURGICAL 139
13.11.1 COMPANY SNAPSHOT 139
13.11.2 PRODUCT PORTFOLIO 139
13.11.3 RECENT DEVELOPMENT 139
13.12 HEBSON 140
13.12.1 COMPANY SNAPSHOT 140
13.12.2 PRODUCT PORTFOLIO 140
13.12.3 RECENT DEVELOPMENT 140
13.13 OLYMPUS CORPORATION 141
13.13.1 COMPANY SNAPSHOT 141
13.13.2 REVENUE ANALYSIS 141
13.13.3 PRODUCT PORTFOLIO 142
13.13.4 RECENT DEVELOPMENT 142
13.13.4.1 Product Launch 142
13.14 OVESCO ENDOSCOPY AG 143
13.14.1 COMPANY SNAPSHOT 143
13.14.2 PRODUCT PORTFOLIO 143
13.14.3 RECENT DEVELOPMENT 143
13.14.3.1 MARKET APPROVAL 143
13.15 PENTAX MEDICAL 144
13.15.1 COMPANY SNAPSHOT 144
13.15.2 REVENUE ANALYSIS 144
13.15.3 PRODUCT PORTFOLIO 145
13.15.4 RECENT DEVELOPMENTS 145
13.15.4.1 JOINT VENTURE 145

13.16 RICHARD WOLF GMBH 146
13.16.1 COMPANY SNAPSHOT 146
13.16.2 PRODUCT PORTFOLIO 146
13.16.3 RECENT DEVELOPMENT 146
13.16.3.1 NEW SUBSIDIARY 146
13.17 SAFEHEAL 147
13.17.1 COMPANY SNAPSHOT 147
13.17.2 PRODUCT PORTFOLIO 147
13.17.3 RECENT DEVELOPMENT 147
13.17.3.1 PARTNERSHIP 147
13.18 SMITH + NEPHEW 148
13.18.1 COMPANY SNAPSHOT 148
13.18.2 REVENUE ANALYSIS 148
13.18.3 PRODUCT PORTFOLIO 149
13.18.4 RECENT DEVELOPMENT 149
13.18.4.1 FDA APPROVAL 149
13.19 SUMMIT HILL LABORATORIES 150
13.19.1 COMPANY SNAPSHOT 150
13.19.2 PRODUCT PORTFOLIO 150
13.19.3 RECENT DEVELOPMENT 150
13.20 SYMMETRY SURGICAL, INC 151
13.20.1 COMPANY SNAPSHOT 151
13.20.2 PRODUCT PORTFOLIO 151
13.20.3 RECENT DEVELOPMENTS 152
13.20.3.1 ACQUISITION 152
13.21 TELEFLEX INCORPORATED 153
13.21.1 COMPANY SNAPSHOT 153
13.21.2 REVENUE ANALYSIS 153
13.21.3 PRODUCT PORTFOLIO 154
13.21.4 RECENT DEVELOPMENT 154
13.21.4.1 CONFERENCE 154
13.22 THE COOPER COMPANIES INC. 155
13.22.1 COMPANY SNAPSHOT 155
13.22.2 REVENUE ANALYSIS 155
13.22.3 PRODUCT PORTFOLIO 156
13.22.4 RECENT DEVELOPMENTS 156
13.22.4.1 ACQUISITION 156

13.23 W. L. GORE & ASSOCIATES, INC 157
13.23.1 COMPANY SNAPSHOT 157
13.23.2 PRODUCT PORTFOLIO 157
13.23.3 RECENT DEVELOPMENT 157
14 QUESTIONNAIRE 158
15 RELATED REPORTS 160

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.